NBF, GPO, and NVI held a joint meeting on Semi-Industrial inactivated H7N9 influenza vaccine.
Date: July 18, 2024
Venue: Prapha Prachaksuphaniti Meeting Room (AD907), 9th Floor, Office of the President Building, KMUTT Bangmod Campus
National Biopharmaceutical Production Pilot Factory (NBF), King Mongkut’s University of Technology Thonburi (KMUTT), in collaboration with the Government Pharmaceutical Organization and the National Vaccine Institute Held the third meeting to discuss cooperation in developing vaccine production using cell culture technology to bring it to a semi-industrial level on July 18, 2024 at Prapha Prachaksuphaniti Meeting Room (AD907), 9th floor, Office of the President, KMUTT, Bangmod.
The purpose of this meeting is to report on the progress of the project to develop the production of an inactivated H7N9 pandemic influenza vaccine using cell culture technology. To expand to a semi-industrial level Under the responsibility of all 3 agencies
This project to develop the production of the H7N9 pandemic influenza vaccine will help Thailand have vaccine security against pandemic influenza. Increase potential for prevention and control of infectious diseases and enhance the country’s ability to produce biological medicines.
The National Biopharmaceutical Production Pilot Factory (NBF), KMUTT, is committed to developing technology and knowledge in the production of biopharmaceuticals. To support the country’s public health policy and build the capacity of domestic personnel and the competitiveness of Thailand’s biopharmaceutical production to be on par with other countries.